Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Development of AI Model for Uveitis Progression and Prognosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04705103
Recruitment Status : Not yet recruiting
First Posted : January 12, 2021
Last Update Posted : January 12, 2021
Sponsor:
Information provided by (Responsible Party):
Haotian Lin, Sun Yat-sen University

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Uveitis is a recurrent inflammation of the eye that can lead to vision loss with various and complicated etiologies. There are many difficulties in uveitis management due to the requirement of long-term monitoring and treatment. This study intends to establish a longitudinal cohort of uveitis patients to colloect multimodal clinical data including visual acuity, intraocular pressure, anterior segment photography, fundus photography, fluoroscopy and other ophthalmic examinations, and final diagnosis in order to use artificial intelligence and deep learning technology to extract ocular features, explore the association with the progression and prognosis of uveitis and finally establish a disease management model for uveitis.

Condition or disease
Uveitis

Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 450 participants
Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 6 Months
Official Title: Development of Artificial Intelligence Prediction Model for Uveitis Progression and Prognosis
Estimated Study Start Date : January 10, 2021
Estimated Primary Completion Date : November 30, 2022
Estimated Study Completion Date : December 30, 2022

Resource links provided by the National Library of Medicine


Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort
initial
relapse
inactive


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. uveitis progression [ Time Frame: up to 1 month ]
    uveitis progression is divided into remission, relapse, or initial


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
  1. Initial stage of uveitis: The first episode of uveitis without treatment;
  2. Remission of uveitis: Uveitis caused by various reasons in the stable disease period of more than 3 months without treatment;
  3. Relapse of uveitis: After discontinuation of uveitis treatment, the disease stabilized for more than 3 months.
Criteria

Inclusion Criteria:

  • Participants who were diagnosed as uveitis, including the initial stage or relapse, or remission of uveitis.

Exclusion Criteria:

  • Participants who cannnot cooperate with ocualr examination.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04705103


Contacts
Layout table for location contacts
Contact: Haotian Lin, M.D.,Ph.D 13802793086 gddlht@aliyun.com
Contact: shuyi Zhang, M.D. 15622177115 shuyi_z@163.com

Sponsors and Collaborators
Sun Yat-sen University
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Haotian Lin, Professor, Sun Yat-sen University
ClinicalTrials.gov Identifier: NCT04705103    
Other Study ID Numbers: 2020KYPJ185
First Posted: January 12, 2021    Key Record Dates
Last Update Posted: January 12, 2021
Last Verified: January 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Uveitis
Uveal Diseases
Eye Diseases